chikungunya
viru
chikv
reemerg
signific
public
health
threat
sinc
chikungunya
fever
epidem
la
driven
medic
import
viru
well
lack
approv
antivir
research
field
chikv
antivir
recent
intensifi
potenti
therapeut
report
show
antichikv
activ
vitro
rang
known
broadspectrum
antivir
like
chloroquin
novel
strategi
involv
rna
silenc
technolog
although
earlier
effort
focus
compound
target
host
compon
recent
studi
report
viral
target
nonstructur
protein
articl
examin
report
vitro
vivo
efficaci
well
therapeut
potenti
antivir
compound
ribavirin
synthet
purin
nucleosid
analog
broadspectrum
antivir
activ
ribavirin
licens
fda
treatment
respiratori
syncyti
viru
chikungunya
viru
chikv
mosquitotransmit
alphaviru
belong
famili
togavirida
chikv
caus
agent
chikungunya
fever
diseas
character
myalgia
polyarthralgia
fever
nausea
headach
maculopapular
rash
owe
mechan
poorli
understood
recurr
persist
myalgia
arthralgia
report
last
year
infect
clear
patient
recent
studi
macaqu
model
suggest
chronic
phase
could
caus
inflammatori
respons
toward
persist
chikv
certain
tissu
rather
autoimmunemedi
respons
initi
believ
chikv
first
isol
plateau
tanzania
earliest
record
epidem
reemerg
chikv
sever
indian
ocean
island
caus
outbreak
unpreced
magnitud
french
island
la
alon
onethird
inhabit
infect
chikv
result
fatal
apart
newfound
pathogen
chikungunya
fever
case
report
la
epidem
also
associ
complic
includ
lymphopenia
lethal
hepat
dermatolog
lesion
enceph
case
fetal
transmiss
also
record
lead
miscarriag
neonat
encephalopathi
apart
classic
transmiss
vector
aed
aegypti
addit
mosquito
vector
aed
albopictu
note
epidem
accompani
mutat
alanin
valin
chikv
glycoprotein
mediat
viral
fusion
albopictu
although
nativ
southeast
asia
today
establish
almost
southern
temper
region
date
chikv
infect
million
peopl
countri
includ
india
malaysia
indonesia
thailand
singapor
usa
itali
cambodia
yemen
despit
medic
threat
pose
chikv
current
approv
antivir
treatment
vaccin
chikv
infect
treatment
usual
symptomat
administr
nonsteroid
antiinflammatori
drug
corticosteroid
control
arthralgia
myalgia
given
effici
mosquito
vector
establish
chikv
infect
mani
geograph
region
urgent
need
develop
safe
effect
antivir
chikv
control
symptom
minim
complic
futur
epidem
reemerg
chikv
recent
year
numer
effort
made
toward
develop
effect
antivir
target
chikv
review
highlight
recent
develop
field
antivir
therapi
chikv
infect
summari
compound
exhibit
antichikv
activ
list
tabl
concentr
compound
produc
total
antichikv
effect
ec
well
concentr
caus
cytotox
cell
cc
also
display
tabl
chikv
replic
cycl
fig
kb
long
consist
two
open
read
frame
kb
frame
encod
viral
nonstructur
protein
kb
frame
encod
viral
structur
protein
includ
capsid
c
envelop
protein
envelop
protein
form
glycoprotein
spike
viral
particl
surfac
initi
bind
hostcel
receptor
facilit
glycoprotein
upon
receptor
bind
viru
particl
endocytos
although
studi
albopictu
cell
line
suggest
endocytosi
chikv
clathrinmedi
studi
mammalian
cell
indic
otherwis
apart
clathrinindepend
endocytosi
mammalian
cell
found
depend
protein
acidif
endosom
result
fusion
viral
envelop
endomos
membran
follow
uncoat
viral
genom
translat
viral
rna
host
cell
translat
machineri
produc
viral
nonstructur
protein
complex
form
chikv
replicas
viral
replicas
gener
copi
viral
genom
well
subgenom
rna
subgenom
rna
encod
structur
polyprotein
process
c
export
plasma
membran
precursor
cleav
furin
yield
matur
protein
final
viral
compon
assembl
nucleocapsid
bud
infect
cell
acquir
lipid
envelop
embed
glycoprotein
inhibit
chikv
entri
present
attract
therapeut
strategi
damag
caus
virul
factor
intracellular
viral
replic
minim
addit
inhibitor
entri
might
target
extracellular
compon
instanc
chikv
replic
cycl
upon
receptor
bind
viru
particl
endocytos
within
endosom
ph
lower
trigger
fusion
viral
envelop
endosom
membran
releas
nucleocapsid
cytoplasm
disassembl
liber
viral
genom
genom
cytoplasm
viral
nonstructur
protein
translat
use
host
translat
machineri
complex
form
viral
replicas
viral
replicas
synthes
negativesens
rna
strand
positivesens
genom
templat
negativesens
rna
serv
templat
gener
two
thing
fulllength
positivesens
genom
becom
packag
new
viral
particl
subgenom
rna
enabl
express
structur
polyprotein
process
cleav
structur
polyprotein
individu
structur
protein
includ
capsid
assembl
togeth
genom
form
nucleocapsid
nucleocapsid
bud
plasma
membran
acquir
portion
host
plasma
membran
embed
viral
glycoprotein
form
envelop
viral
particl
abbrevi
nsp
nonstructur
protein
er
endoplasm
reticulum
precursor
hostcel
receptor
access
therebi
reduc
requir
dosag
limit
cytotox
search
specif
entri
inhibitor
howev
imped
poor
understand
chikvspecif
receptor
human
cellular
target
fact
singl
put
chikv
receptor
prohibitin
identifi
date
identif
chikvspecif
receptor
especi
implic
vivo
pathogenesi
chikv
infect
crucial
drive
futur
research
chikv
entri
inhibitor
chloroquin
antimalari
drug
shown
antivir
activ
sever
virus
includ
hiv
sever
acut
respiratori
syndrom
coronaviru
alphavirus
dosedepend
inhibit
chikv
replic
vero
cell
observ
upon
treatment
chloroquin
infect
investig
mechan
chloroquin
action
suggest
chloroquin
disrupt
endosomemedi
chikv
intern
possibl
prevent
endosom
acidif
author
also
note
ec
valu
differ
treatment
group
mm
pretreat
mm
cotreat
mm
posttreat
similar
plasma
concentr
chloroquin
treatment
acut
malaria
indic
potenti
use
chikv
infect
vivo
despit
doubleblind
clinic
trial
conduct
chikv
patient
la
epidem
fail
show
signific
improv
symptom
decreas
durat
viremia
upon
administr
chloroquin
day
day
mg
day
mg
twice
daili
day
mg
convers
day
patient
chloroquin
treatment
group
complain
frequent
chronic
arthralgia
p
placebo
group
contrast
brighton
report
signific
improv
chronic
arthriti
symptom
upon
chloroquin
phosphat
treatment
mgday
week
ten
patient
suffer
chronic
arthralgia
least
year
follow
chikv
infect
must
note
vitro
studi
perform
multipl
infect
moi
might
reflect
true
viremia
acut
phase
chikv
infect
inde
viral
load
observ
reach
copi
viral
genom
per
ml
serum
acut
infect
clinic
trial
conduct
patient
cohort
small
conclus
data
effect
chloroquin
obtain
addit
differ
treatment
length
chloroquin
trial
could
effect
patient
outcom
discrep
data
chloroquin
treatment
also
observ
patient
savarino
et
al
observ
decreas
viral
load
patient
signific
studi
lower
dose
chloroquin
use
author
note
import
use
appropri
dosag
treatment
regimen
therefor
dismiss
chloroquin
potenti
antivir
studi
need
perform
determin
whether
chang
treatment
regimen
would
impact
viral
load
symptom
arbidol
broadspectrum
antivir
approv
russia
china
treatment
prophylaxi
influenza
respiratori
infect
arbidol
shown
exhibit
potent
inhibitori
effect
chikv
infect
cell
ec
mm
cc
mm
arbidolresist
mutant
strain
isol
studi
display
mutat
glycin
arginin
domain
chikv
glycoprotein
postul
involv
bind
host
receptor
taken
togeth
data
hemagglutin
assay
studi
suggest
observ
influenza
virus
arbidol
inhibit
viral
entri
prevent
adsorpt
chikv
target
cell
clinic
use
year
russia
arbidol
shown
welltoler
minim
side
effect
addit
arbidolresist
virus
isol
date
suggest
might
attract
option
antivir
antivir
screen
conduct
temperaturesensit
sfv
mutant
identifi
entri
inhibitor
also
report
effect
recombin
strain
chikv
carri
luciferas
gene
compris
six
compound
contain
core
tabl
includ
chlorpromazin
perphenazin
ethopropazin
thiethylperazin
thioridazin
methdilazin
ec
mm
phenothiazin
clinic
approv
antipsychot
abil
transvers
bloodbrain
barrier
could
use
chikv
case
neurolog
complic
similar
document
la
outbreak
select
phenothiazin
expect
inhibit
chikv
entri
sfv
studi
identifi
molecular
target
remain
conduct
like
rna
virus
translat
chikv
genom
carri
host
cell
translat
machineri
rna
interfer
rnai
offer
promis
approach
toward
inhibit
viral
protein
express
select
target
viral
genom
templat
small
interf
rna
sirna
sequenc
target
chikv
gene
report
reduc
chikv
titer
genom
copi
number
significantli
p
log
unit
hour
postinfect
hpi
inhibit
howev
found
transient
diminish
hpi
possibl
owe
rapidli
replic
natur
alphavirus
suscept
sirna
intracellular
degrad
recent
plasmidbas
small
hairpin
rna
shrna
evalu
potenti
chikv
antivir
stabl
cell
clone
express
shrna
chikv
display
signific
p
sustain
inhibit
chikv
infect
protein
product
least
day
postinfect
infecti
titer
decreas
progress
day
postinfect
day
postinfect
chikv
replic
complet
abolish
inocul
mg
shrna
suckl
mous
model
hour
infect
plaqueform
unit
pfu
chikv
result
complet
surviv
treat
group
day
postinfect
contrast
control
group
inocul
scrambl
shrna
display
complet
mortal
within
day
postinfect
target
specif
confirm
stabl
shrna
clone
show
decreas
viral
titer
upon
infect
sinv
dengu
viru
approv
vitraven
fomivirsen
fda
treatment
retin
follow
cytomegaloviru
infect
suggest
rnai
technolog
potenti
develop
therapeut
applic
efficaci
sirna
vitro
shrna
vivo
suggest
rnai
could
use
combat
chikv
infect
well
despit
transient
action
sirna
treatment
could
use
lower
viral
titer
aid
host
immun
respons
clear
infect
shrna
efficaci
vivo
show
promis
efficaci
prophylaxi
potenti
use
postinfect
must
also
explor
harringtonin
cephalotaxin
alkaloid
deriv
cephalotaxu
harringtonia
display
potent
inhibit
chikv
infect
ec
mm
minim
cytotox
investig
reveal
harringtonin
inhibit
product
protein
positiveand
negativesens
chikv
rna
caus
reduct
infecti
chikv
titer
harringtonin
found
inhibit
elong
phase
eukaryot
translat
compet
incom
aminoacyl
trna
bind
site
ribosom
subunit
author
therefor
postul
antivir
action
harringtonin
could
also
depend
inhibit
eukaryot
translat
machineri
directli
interrupt
nonstructur
structur
viral
protein
synthesi
indirectli
affect
downstream
product
homoharringtonin
analog
harringtonin
addit
methyl
group
also
observ
possess
antichikv
activ
interestingli
harringtonin
homoharringtonin
display
greater
potenc
chikv
strain
carri
mutat
compar
strain
carri
wild
type
howev
causal
link
mutat
differ
drug
potenc
establish
isol
use
studi
contain
genet
differ
homoharringtonin
omacetaxin
mepesuccin
recent
approv
fda
treatment
chronic
myeloid
leukemia
although
harringtonin
homoharringtonin
report
possess
antileukemia
properti
homoharringtonin
observ
potent
owe
abil
persist
target
site
longer
durat
extens
vivo
studi
suitabl
murin
model
requir
determin
whether
harringtonin
homoharringtonin
suitabl
chikv
therapeut
although
initi
step
chikv
replic
cycl
employ
host
factor
replic
viral
genom
repres
step
driven
mainli
viral
factor
pohjala
et
al
develop
screen
assay
use
bhkchikvnct
stabl
cell
line
express
chikv
replicon
contain
nonstructur
protein
enhanc
green
fluoresc
protein
renilla
luciferas
report
four
natur
compound
contain
structur
identifi
chikv
inhibitor
compound
known
anticanc
properti
like
apigenin
chrysin
naringenin
silybin
ec
mm
prothipendyl
pharmaceut
phenothiazin
also
identifi
ec
mm
given
alphaviru
replicas
found
complex
host
protein
well
necessari
verifi
target
select
hit
compound
downstream
studi
import
structur
also
evalu
studi
mechan
sar
analysi
effort
identifi
novel
antivir
also
driven
isol
new
compound
natur
sourc
allard
et
al
perform
bioassayguid
purif
extract
bark
trigonostemon
cherrieri
screen
inhibitor
rnadepend
rna
polymeras
portion
dengu
viru
protein
screen
author
isol
new
seri
highli
oxygen
daphnan
diterpenoid
orthoest
carri
uncommon
chlorin
moieti
trigocherrin
b
f
trigocherriolid
b
c
suppress
chikvinduc
cytopath
effect
cpe
ec
mm
cc
mm
among
select
indic
si
cc
ec
trigocherrin
si
significantli
higher
trigocherriolid
si
suggest
trigocherrin
potent
inhibitor
chikv
infect
given
target
approach
use
screen
assay
possibl
compound
inhibit
chikv
replicas
howev
precis
target
mechan
action
diterpenoid
yet
investig
chikv
model
chikv
carri
proteas
domain
involv
process
viral
polyprotein
rna
triphosphatas
involv
viral
rna
cap
nucleotid
triphosphatas
support
rna
helicas
function
chikv
also
found
inhibit
host
antivir
respons
suppress
transcript
type
iii
interferonstimul
jakstat
signal
mutat
region
found
inhibit
chikv
replic
affirm
attract
target
chikv
antivir
lucashourani
et
al
design
transreport
assay
screen
inhibitor
chikv
screen
natur
compound
deriv
ec
mm
valid
inhibitor
chikv
infect
vitro
use
recombin
chikv
strain
carri
luciferas
insert
sever
compound
similar
taxoid
oxetan
ring
structur
found
minim
activ
transreport
assay
suggest
work
need
done
determin
sar
bassetto
et
al
develop
homolog
model
chikv
base
crystal
structur
venezuelan
equin
enceph
viru
veev
relat
alphaviru
virtual
screen
five
million
compound
author
identifi
lead
compound
compound
suppress
chikvinduc
cpe
ec
mm
cc
mm
compound
predict
bind
central
portion
proteas
activ
site
sar
analysi
conduct
structur
analog
suggest
cyclopropyl
moieti
hydrazon
group
compound
import
antichikv
activ
combin
pegyl
interferon
ifn
treatment
acut
relaps
hepat
c
viru
hcv
ribavirin
display
potent
inhibit
chikvinduc
cpe
ec
mm
cc
mm
well
signific
p
dosedepend
reduct
chikv
titer
concord
previou
data
ribavirin
also
display
synergist
antivir
effect
ifna
studi
conduct
patient
experienc
arthriti
lower
limb
pain
least
week
chikv
infect
found
administr
ribavirin
mg
twice
day
day
reduc
soft
tissu
swell
joint
pain
six
ten
patient
treat
abl
walk
freeli
upon
ribavirin
treatment
seven
patient
requir
analges
week
despit
promis
data
patient
cohort
use
small
conclus
observ
efficaci
ribavirin
howev
observ
vitro
vivo
antichikv
activ
ribavirin
warrant
studi
potenti
antivir
use
despit
welldocu
antivir
effect
mechan
action
ribavirin
remain
controversi
like
vari
differ
virus
structur
analog
guanosin
ribavirin
known
competit
inhibitor
inosin
monophosph
dehydrogenas
impdh
enzym
involv
de
novo
synthesi
guanin
nucleotid
studi
sinv
shown
ribavirin
treatment
deplet
intracellular
guanosin
triphosph
gtp
pool
resist
ribavirin
map
guanylyltransferas
involv
cap
viral
rna
therefor
possibl
ribavirin
result
increas
degrad
intracellular
viral
rna
halt
capdepend
viral
protein
translat
howev
mechanist
studi
still
requir
confirm
elucid
mode
action
ribavirin
chikv
inhibit
chikv
replic
cpe
noncytotox
concentr
ec
mm
cc
mm
like
ribavirin
nucleosid
analog
demonstr
broadspectrum
antivir
activ
howev
antivir
activ
difficult
replic
vivo
uridin
analog
inhibitor
orotidin
monophosph
decarboxylas
involv
de
novo
synthesi
pyrimidin
clinic
triacet
use
treatment
sever
psoriasi
without
sever
advers
effect
administ
high
dose
mgkg
reach
plasma
concentr
higher
level
requir
alphaviru
inhibit
suggest
possibl
therapeut
use
apart
mechanist
studi
efficaci
requir
care
evalu
suitabl
vivo
model
chikv
infect
mycophenol
acid
mpa
noncompetit
inhibitor
impdh
use
clinic
immunosuppress
prevent
reject
transplant
organ
mpa
appear
inhibit
chikv
replic
mechan
similar
ribavirin
vitro
mpa
inhibit
chikvinduc
cpe
across
differ
moi
dosedepend
manner
ec
mm
moi
mm
moi
cc
mm
dosedepend
reduct
chikv
genom
copi
number
infecti
titer
also
note
mode
action
mpa
trace
deplet
gtp
pool
subsequ
inhibit
chikvinduc
apoptosi
result
decreas
cpe
addit
exogen
guanosin
monophosph
gmp
abolish
mpainduc
inhibit
chikv
infect
mparesist
sinv
strain
display
mutat
result
guanylyl
methyltransferas
increas
affin
gtp
possibl
similar
mechan
could
appli
chikv
addit
author
note
mpa
treatment
caus
reduct
infect
chikv
suggest
addit
mechan
mpa
action
could
reli
increas
mutat
rate
viral
genom
replic
owe
lack
intracellular
gtp
chikv
infect
clear
rapidli
within
day
suggest
crucial
role
innat
immun
system
acut
phase
infect
virus
type
ifn
play
central
role
chikv
infect
clearanc
product
type
ifn
believ
trigger
detect
viral
rna
tolllik
receptor
tlr
well
riglik
receptor
chikv
infect
type
ifn
activ
transcript
interferonstimul
gene
isg
encod
protein
involv
host
antivir
defens
therefor
activ
innat
immun
respons
may
contribut
quicker
effici
resolut
viral
infect
ifna
treatment
report
protect
mice
infect
veev
sfv
nerurovirul
sinv
ec
iuml
cc
iuml
ec
iuml
cc
iuml
caus
dosedepend
inhibit
cpe
chikv
titer
observ
harringtonin
studi
bordi
et
al
note
chikv
strain
carri
mutat
sensit
ifna
treatment
strain
carri
wildtyp
genotyp
protect
chikvinduc
cpe
vanish
upon
treatment
iuml
ifna
isol
mutat
oppos
iuml
wildtyp
isol
howev
author
clarifi
genet
background
isol
unknown
addit
genet
differ
could
contribut
observ
nevertheless
worthwhil
ascertain
effect
mutat
antivir
given
isol
carri
mutat
becam
preval
epidem
progress
la
evid
vitro
antivir
effect
ifna
well
synergist
effect
ifna
ribavirin
warrant
explor
suitabl
vivo
model
polyinosin
acid
polycytidyl
acid
poli
c
synthet
analog
doublestrand
rna
dsrna
interact
caus
potent
induct
ifn
treatment
mgml
poli
c
chikv
infect
variou
moi
suppress
cpe
hpi
treatment
condit
chikv
infecti
titer
reduc
log
unit
hpi
log
unit
hpi
moi
test
downstream
studi
indic
poli
c
treatment
induc
secret
ifnb
peak
hour
posttreat
oppos
chikvinduc
secret
ifnb
peak
hpi
express
also
upregul
poli
c
treatment
well
chikv
infect
signific
upregul
mrna
level
observ
ifna
ifnb
interferoninduc
antivir
factor
includ
oligoadenyl
synthetas
oa
myxoviru
resist
protein
mxa
upon
poli
c
treatment
uninfect
cell
probabl
antivir
effect
poli
c
depend
immunomodulatori
effect
poli
c
also
use
adjuv
vaccin
research
anoth
possibl
applic
analog
final
stage
chikv
replic
cycl
viral
precursor
protein
cleav
furin
matur
treatment
chikvinfect
cell
decanoylrvkrchloromethyl
keton
decrvkrcmk
furin
inhibitor
found
suppress
level
chikv
infect
determin
immunofluoresc
detect
alphaviru
nucleocapsid
particular
author
observ
inhibit
correl
decreas
number
antigenposit
cell
per
chikvinduc
focu
instead
deplet
number
foci
impli
decrvkrcmk
impair
spread
chikv
neighbor
cell
treatment
decrvkrcmk
chikv
infect
also
reveal
signific
inhibit
viral
titer
indic
decrvkrcmk
could
inhibit
earli
step
viral
replic
cycl
well
howev
mechanist
studi
investig
perform
bourjout
et
al
isol
novel
tiglian
diterpenoid
trigowiin
chemic
studi
trigonostemon
howii
although
trigowiin
ec
mm
cc
mm
display
moder
antichikv
activ
sever
wellknown
tiglian
diterpenoid
similar
structur
display
potent
inhibit
chikvinduc
cpe
includ
prostratin
ec
mm
cc
mm
tpa
ec
mm
cc
mm
ec
mm
cc
mm
particular
tpa
potent
compound
set
si
base
preliminari
sar
data
author
propos
antivir
activ
chikv
requir
basic
phorbol
carbon
skeleton
esterifi
posit
free
hydroxyl
group
posit
despit
attract
select
index
tumorpromot
properti
tpa
could
make
unsuit
antivir
agent
addit
tpa
report
inhibit
hivinduc
syncytia
format
via
protein
kinas
c
pkc
depend
pathway
enhanc
hiv
replic
indic
antivir
activ
compound
display
cpe
reduct
alway
confirm
assay
determin
infecti
viral
titer
especi
tpa
structur
analog
given
data
hiv
studi
magnitud
chikungunya
fever
epidem
la
emphas
import
search
appropri
chikv
antivir
antivir
discuss
review
preliminari
stage
research
attribut
partli
gap
current
understand
biolog
alphavirus
among
potenti
therapeut
discuss
wellknown
broadspectrum
antivir
like
chloroquin
ribavirin
ifna
display
efficaci
vivo
clinic
approv
condit
exist
inform
pharmacolog
paramet
compound
might
aid
moreextens
vivo
studi
antichikv
properti
expedit
drug
develop
process
recent
discoveri
novel
antivir
target
chikv
compon
like
compound
replicas
complex
viral
genom
translat
sirna
shrna
shown
promis
vitro
studi
vivo
efficaci
warrant
especi
compound
viral
target
expect
display
lower
toxic
owe
select
nevertheless
compound
host
target
like
harringtonin
ribosom
inhibitor
decrvkrcmk
furin
inhibitor
remain
relev
antivir
discoveri
process
shown
fda
approv
hosttarget
compound
like
ribavirin
lot
remain
unknown
regard
chikv
biolog
pathogenesi
vivo
date
process
contribut
chikvinduc
enceph
chronic
arthriti
poorli
understood
pose
hindranc
antivir
drug
discoveri
even
molecular
level
gap
understand
chikv
replic
includ
hostcel
receptor
well
event
prior
viral
bud
inde
research
basic
biolog
vivo
pathogenesi
chikv
crucial
identif
novel
viral
target
well
antivir
